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del(9p) G- banding - Courtesy Jean-Luc Lai and Alain 
Vanderhaegen. 
Clinics and pathology 
Disease 
Acute lymphocycic leukemia (ALL). 
Phenotype/cell stem origin 
Lack of specificity for a particular immunophenotype. 
Epidemiology 
Approximately 10% of childhood ALL, similar in adult 
ALL. 
Prognosis 
Recent data indicate that an abnormal 9p is an adverse 
risk factor for B-lineage, but not T-lineage pediatric 
patients; this is more pronounced in standard-risk 
patients (age 1 - 9 years with WBC count <50 X 109/l); 
a dic(9;12)(p11-13;p11-12) has been reported to have a 








Various aberrations result in an abnormal 9p; these 
include monosomy 9, del(9p), add(9p), 
der(9)t(V;9)(V;p), dic(V;9)(V;p), i(9q) and balanced 
translocations with 9p breakpoints; dicentric 
chromosomes in ALL nearly always involve a 
chromosome 9; an abnormal 9p usually occurs as part 
of a more complex karyotype; it occurs as a sole 
aberration in less than 10% of cases with an abnormal 
9p. 
Additional anomalies 
Additional anomalies are frequent; an abnormal 12p is 
particularly frequent (16% of cases), and a deletion of 
6q is also frequent (11% of cases). 
Genes involved and proteins 
Note 
The different types of 9p aberrations may have 
different molecular consequences; when a deletion of 
9p occurs, the genes involved colud be MTS1 / CDK4I 
/ p16INK4A (CDKN2) and MTS2 / p15INK4B 
(CDKN2B); these are believed to be tumor suppressor 
genes, and loss of heterozygosity occurs more 
frequently than cytogenetic deletions of 9p; however, 
mutation of the remaining allele is infrequent, and 
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